MMP14 and colitis: Evidence from human samples confirms that this pathway is active in IBD, and blockade of DSS‐induced colitis in mice with an MT1‐MMP inhibitory antibody or a TSP1‐targeting peptide indicates the potential of this strategy to improve IBD.